With Alzheimer's in its sights, Alnylam shares data on getting siRNA to targets beyond the liver Zosano goes bankrupt after FDA rejects migraine drug delivery patch Bubbling up: Arcutis’ foam hits mark in skin disorder phase 3 to clear path to FDA filing Zylö scoops cash to advance topical delivery particle technology Fierce Healthcare and Fierce MedTech's 17 rising stars in health tech 'The Top Line' podcast: COVID therapies dominate 2021's top-selling drugs, raising the curtain on ASCO 2022, plus this week's headlines Featured Story | By Nick Paul Taylor Alnylam has set out how it plans to deliver siRNA to the central nervous system and other tissues beyond the liver. Writing in Nature Biotechnology, the RNA specialist shared details of how the conjugation of its drug candidates enabled the therapeutic silencing of target genes around the body in preclinical studies. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Zosano Pharma has run out of road. After working to find a strategic alternative in the wake of the FDA’s refusal to review its submission, the transdermal drug delivery specialist has now filed for paperwork for Chapter 11 bankruptcy. read more By Nick Paul Taylor Arcutis Biotherapeutics has delivered a phase 3 win for its roflumilast foam formulation. With the cream version already under review at the FDA in plaque psoriasis, the topical drug delivery specialist has now gathered up the data to support a filing for the foam variant in seborrheic dermatitis. read more By Nick Paul Taylor Zylö Therapeutics has secured funding to advance its Z-pod topical delivery particles, putting together a $5.2 million series B round to support work on a technology with applications in erectile dysfunction and cutaneous lupus. read more By Conor Hale,Heather Landi Fierce Healthcare and Fierce Medtech compiled a list highlighting some of the biggest rising stars in the health tech industry, spanning the fields of artificial intelligence, software development and health IT. read more By Teresa Carey This week on "The Top Line," we discuss our special report on the top 20 drugs by 2021 sales, and it is no surprise that products that fight COVID-19 dominated the biopharma landscape. We also talk about this weekend’s ASCO meeting and the week's other big headlines. Plus, we have bloopers! read more Resources Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? AI Driven Drug Discovery Summit August 16-17, 2022 Fierce Health Payer Summit October 12, 2022 | Free Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Drug Development Boot Camp® 2022 November 16-17, 2022 Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Free Virtual Event | 